Literature DB >> 22167501

Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases.

D-M Koh1, D J Collins, T Wallace, I Chau, A M Riddell.   

Abstract

OBJECTIVES: To compare the diagnostic accuracy of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MRI, diffusion-weighted MRI (DW-MRI) and a combination of both techniques for the detection of colorectal hepatic metastases.
METHODS: 72 patients with suspected colorectal liver metastases underwent Gd-EOB-DTPA MRI and DW-MRI. Images were retrospectively reviewed with unenhanced T(1) and T(2) weighted images as Gd-EOB-DTPA image set, DW-MRI image set and combined image set by two independent radiologists. Each lesion detected was scored for size, location and likelihood of metastasis, and compared with surgery and follow-up imaging. Diagnostic accuracy was compared using receiver operating characteristics and interobserver agreement by kappa statistics.
RESULTS: 417 lesions (310 metastases, 107 benign) were found in 72 patients. For both readers, diagnostic accuracy using the combined image set was higher [area under the curve (Az)=0.96, 0.97] than Gd-EOB-DTPA image set (Az=0.86, 0.89) or DW-MRI image set (Az=0.93, 0.92). Using combined image set improved identification of liver metastases compared with Gd-EOB-DTPA image set (p<0.001) or DW-MRI image set (p<0.001). There was very good interobserver agreement for lesion classification (κ=0.81-0.88).
CONCLUSIONS: Combining DW-MRI with Gd-EOB-DTPA-enhanced T(1) weighted MRI significantly improved the detection of colorectal liver metastases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167501      PMCID: PMC3474082          DOI: 10.1259/bjr/91771639

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  23 in total

Review 1.  Artifacts and pitfalls in diffusion MRI.

Authors:  Denis Le Bihan; Cyril Poupon; Alexis Amadon; Franck Lethimonnier
Journal:  J Magn Reson Imaging       Date:  2006-09       Impact factor: 4.813

2.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

3.  Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT.

Authors:  C Valls; E Andía; A Sánchez; A Gumà; J Figueras; J Torras; T Serrano
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

4.  Preoperative detection of hepatic metastases: comparison of diffusion-weighted, T2-weighted fast spin echo and gadolinium-enhanced MR imaging using surgical and histopathologic findings as standard of reference.

Authors:  Philippe Soyer; Mourad Boudiaf; Vinciane Placé; Marc Sirol; Karine Pautrat; Alexandre Vignaud; Fabrice Staub; Djamel Tiah; Lounis Hamzi; Florent Duchat; Yann Fargeaudou; Marc Pocard
Journal:  Eur J Radiol       Date:  2010-07-21       Impact factor: 3.528

5.  Measurement of the apparent diffusion coefficient in the liver: is it a reliable index for hepatic disease diagnosis?

Authors:  Katsuhiro Nasu; Yoshifumi Kuroki; Ryuzo Sekiguchi; Toshiki Kazama; Hiroto Nakajima
Journal:  Radiat Med       Date:  2006-07

6.  Small (<or= 2 cm) hepatic lesions in colorectal cancer patients: detection and characterization on mangafodipir trisodium-enhanced MRI.

Authors:  Kyoung Won Kim; Ah Young Kim; Tae Kyoung Kim; Seong Ho Park; Hyun Jin Kim; Young Kyung Lee; Mi-Suk Park; Hyun Kwon Ha; Pyo Nyun Kim; Jin Cheon Kim; Moon-Gyu Lee
Journal:  AJR Am J Roentgenol       Date:  2004-05       Impact factor: 3.959

7.  Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT.

Authors:  Carlo Bartolozzi; Francescamaria Donati; Dania Cioni; Carlo Procacci; Giovanni Morana; Antonio Chiesa; Luigi Grazioli; Giorgio Cittadini; Giuseppe Cittadini; Andrea Giovagnoni; Giovanni Gandini; Jochen Maass; Riccardo Lencioni
Journal:  Eur Radiol       Date:  2003-08-09       Impact factor: 5.315

8.  Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging.

Authors:  Katsuhiro Nasu; Yoshihumi Kuroki; Shigeru Nawano; Seiko Kuroki; Tatsuaki Tsukamoto; Seiji Yamamoto; Ken Motoori; Takuya Ueda
Journal:  Radiology       Date:  2006-02-21       Impact factor: 11.105

Review 9.  Diffusion-weighted MRI in the body: applications and challenges in oncology.

Authors:  Dow-Mu Koh; David J Collins
Journal:  AJR Am J Roentgenol       Date:  2007-06       Impact factor: 3.959

Review 10.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

Authors:  Christoph J Zech; Karin A Herrmann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

View more
  22 in total

1.  The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography.

Authors:  Cindy Chew; Patrick J O'Dwyer
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

2.  Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?

Authors:  Seung Soo Kim; Kyoung Doo Song; Young Kon Kim; Hee Cheol Kim; Jung Wook Huh; Young Suk Park; Joon Oh Park; Seung Tae Kim
Journal:  Eur Radiol       Date:  2016-11-04       Impact factor: 5.315

Review 3.  Diffusion-weighted MRI of the liver: challenges and some solutions for the quantification of apparent diffusion coefficient and intravoxel incoherent motion.

Authors:  Yi Xiang J Wang; Hua Huang; Cun-Jing Zheng; Ben-Heng Xiao; Olivier Chevallier; Wei Wang
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15

4.  Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy.

Authors:  Mi Hye Yu; Jeong Min Lee; Bo Yun Hur; Tae-You Kim; Seung-Yong Jeong; Nam-Joon Yi; Kyung-Suk Suh; Joon Koo Han; Byung-Ihn Choi
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

5.  Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy.

Authors:  Annalisa Macera; Chiara Lario; Massimo Petracchini; Teresa Gallo; Daniele Regge; Irene Floriani; Dario Ribero; Lorenzo Capussotti; Stefano Cirillo
Journal:  Eur Radiol       Date:  2012-09-14       Impact factor: 5.315

6.  Selection for hepatic resection of colorectal liver metastases: expert consensus statement.

Authors:  Reid B Adams; Thomas A Aloia; Evelyne Loyer; Timothy M Pawlik; Bachir Taouli; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

7.  Fat confounds the observed apparent diffusion coefficient in patients with hepatic steatosis.

Authors:  Jan Hansmann; Diego Hernando; Scott B Reeder
Journal:  Magn Reson Med       Date:  2012-11-14       Impact factor: 4.668

8.  Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.

Authors:  Karianne G Fleten; Kine M Bakke; Gunhild M Mælandsmo; Andreas Abildgaard; Kathrine Røe Redalen; Kjersti Flatmark
Journal:  Clin Exp Metastasis       Date:  2016-11-03       Impact factor: 5.150

Review 9.  Diffusion-weighted imaging of the liver: techniques and applications.

Authors:  Sara Lewis; Hadrien Dyvorne; Yong Cui; Bachir Taouli
Journal:  Magn Reson Imaging Clin N Am       Date:  2014-08       Impact factor: 2.266

10.  A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases.

Authors:  Valérie Vilgrain; Maxime Esvan; Maxime Ronot; Aurore Caumont-Prim; Christophe Aubé; Gilles Chatellier
Journal:  Eur Radiol       Date:  2016-02-16       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.